DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Looking for a particular Lexaria Bioscience employee's phone or email?
Lexaria Bioscience Questions
The Lexaria Bioscience annual revenue was $87 million in 2026.
Rich Christopher is the Chief Executive Officer | BOD Member of Lexaria Bioscience.
8 people are employed at Lexaria Bioscience.
Lexaria Bioscience is based in Kelowna, British Columbia.
The NAICS codes for Lexaria Bioscience are [6215, 5419, 62, 621, 62151, 541, 54199, 54].
The SIC codes for Lexaria Bioscience are [87, 873, 80, 807].
Top Lexaria Bioscience Employees
-
15+
-
25+
-
55+
-
George J.
Head of Investor Relations at Lexaria Bioscience
Calgary, AB, CA2 -
Jessica Bauer
Financial Controller at Lexaria Bioscience
Kelowna, BC, CA2 -
Vanessa Carle
Head Of Legal Department at Lexaria Bioscience
Kelowna, BC, CA3
Related Companies
